中文字幕丝袜在线56页_亚洲另类色区欧美日韩_国产精品国色综合久久_国产a一级毛片午夜剧场14,天天色综合天天,日本免费一区二区三区四区五六区,99精品免费视频

更新于 1月13日

財務(wù)BP-生產(chǎn)方向(J16389)

2.6萬-4萬·16薪
  • 上海徐匯區(qū)
  • 5-10年
  • 本科
  • 全職
  • 招1人

職位描述

生產(chǎn)財務(wù)BP
崗位職責(zé):
1.As Production/Quality/Engineering/supporting/CDMO/CRO team business partner, support their daily operation in finance area, including but not limited in policy guidance, compliance, business process improvement, business growth suggestion, cost reduction.
2.Actual performance analysis and reporting including cost center spending analysis, product cost variance analysis, inventory analysis, CAPEX investment analysis, HC utilization, equipment utilization, and other required analysis.
3.Cost estimation simulation for business changes and decisions.
4.Annual budget and regular forecast
5.Budget control and cost reduction with the team to continuously improve product cost structure, MRP, purchasing, inventory and other related area.
6.Supporting purchasing price negotiation with vendor, to achieve the corporate continuous cost reduction.
7.Tracking CAPEX investment and control spending speed.
8.Co-ordination and support with other finance BPs and functions.
9.Lead or attend digital transformation projects like SAP,BI.
10.Other tasks required by supported teams and the company.

任職要求:
1. Bachelor degree, major in accounting or related.
2. Over 8 years working experience and over 3 years overall manufacture BP/controller expense is must.
3. Bio pharmacy production plant experience is preferred.
4. Work independently, can work under pressure and result driven
5. Smart, fast learning and with highly EQ
6. Coordination, willing to team working and growth together with team
7. Flexibility, willing to take the challenge from various function.

工作地點(diǎn)

華鑫慧享城B區(qū)8棟11樓

職位發(fā)布者

鄒女士/HR

今日活躍
立即溝通
公司Logo上海復(fù)宏漢霖生物技術(shù)股份有限公司
復(fù)宏漢霖(2696.HK)是一家國際化的創(chuàng)新生物制藥公司,致力于為全球患者提供可負(fù)擔(dān)的高品質(zhì)生物藥,產(chǎn)品覆蓋腫瘤、自身免疫疾病、眼科疾病等領(lǐng)域,已在中國上市5款產(chǎn)品,在國際上市1款產(chǎn)品,18項(xiàng)適應(yīng)癥獲批,3個上市申請分別獲中國藥監(jiān)局、美國FDA和歐盟EMA受理。自2010年成立以來,復(fù)宏漢霖已建成一體化生物制藥平臺,高效及創(chuàng)新的自主核心能力貫穿研發(fā)、生產(chǎn)及商業(yè)運(yùn)營全產(chǎn)業(yè)鏈。公司已建立完善高效的全球創(chuàng)新中心,按照國際藥品生產(chǎn)質(zhì)量管理規(guī)范(GMP)標(biāo)準(zhǔn)進(jìn)行生產(chǎn)和質(zhì)量管控,不斷夯實(shí)一體化綜合生產(chǎn)平臺,其中,上海徐匯基地已獲得中國和歐盟GMP認(rèn)證,松江基地(一)也已獲得中國GMP認(rèn)證。復(fù)宏漢霖前瞻性布局了一個多元化、高質(zhì)量的產(chǎn)品管線,涵蓋20多種創(chuàng)新單克隆抗體,并全面推進(jìn)基于自有抗PD-1單抗H藥漢斯?fàn)?的腫瘤免疫聯(lián)合療法。繼國內(nèi)首個生物類似藥漢利康?(利妥昔單抗)、中國首個自主研發(fā)的中歐雙批單抗藥物漢曲優(yōu)?(曲妥珠單抗,歐洲商品名:Zercepac?,澳大利亞商品名:Tuzucip?和Trastucip?)、漢達(dá)遠(yuǎn)?(阿達(dá)木單抗)和漢貝泰?(貝伐珠單抗)相繼獲批上市,創(chuàng)新產(chǎn)品漢斯?fàn)?(斯魯利單抗)已獲批用于治療微衛(wèi)星高度不穩(wěn)定(MSI-H)實(shí)體瘤、鱗狀非小細(xì)胞肺癌和廣泛期小細(xì)胞肺癌,成為全球首個獲批一線治療小細(xì)胞肺癌的抗PD-1單抗,其食管鱗狀細(xì)胞癌適應(yīng)癥的上市注冊申請也正在審評中。公司亦同步就16個產(chǎn)品在全球范圍內(nèi)開展30多項(xiàng)臨床試驗(yàn)。
公司主頁
主站蜘蛛池模板: 云阳县| 奉节县| 平阴县| 酒泉市| 泾川县| 安图县| 宜州市| 万山特区| 文安县| 临猗县| 积石山| 黑龙江省| 呈贡县| 霍州市| 乌兰浩特市| 康平县| 哈密市| 柳州市| 玛多县| 岳阳市| 普兰店市| 绥化市| 建水县| 抚远县| 邵阳市| 黄骅市| 西峡县| 靖江市| 德令哈市| 汾阳市| 罗源县| 梁河县| 蛟河市| 修武县| 潼南县| 高雄县| 根河市| 昌乐县| 广州市| 大邑县| 和政县|